ZIMMER BIOMET HOLDINGS INC

ISIN: US98956P1021 WKN: 98956P102 Asset Class: Stock



Company Profile

Delenes notes

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw. IN.

Financial figures, Fiscal year: from 01.01. to 31.12.						
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Current assets	4,609,500,000		4,427,300,000		4,885,000,000	
Common stock capital		3,200,000		3,100,000		3,100,000
Fixed assets	16,887,400,000		16,638,700,000		18,571,400,000	
Equity capital of a company		12,488,200,000		12,027,000,000		12,666,400,000
Cash and cash equivalents	415,800,000		375,700,000		478,500,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,857,400,000		2,358,200,000		3,467,900,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		6,151,300,000		6,680,800,000		7,322,100,000
Different income		-		-		-
Other liabilities		751,400,000		886,500,000		972,600,000
Total assets	21,496,900,000	21,496,900,000	21,066,000,000	21,066,000,000	23,456,400,000	23,456,400,000

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	18,000	18,000	19,500
Equity ratio	58.13%	57.12%	54.02%
Debt-equity ratio	72.03%	75.06%	85.10%

Others			
	2023	2022	2021
Tax Expense Rate	3.95%	27.83%	3.90%

ZIMMER BIOMET HOLDINGS INC

ISIN: US98956P1021 WKN: 98956P102 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	7,394,200,000	6,939,900,000	7,836,200,000
Net income	1,024,000,000	290,200,000	401,600,000
EBIT	1,188,864,160	534,452,160	589,629,920
Operating income before taxes	1,067,300,000	403,500,000	418,400,000
Cash Flow	1,581,600,000	1,284,700,000	1,499,200,000
Net interest income	-195,300,000	-164,100,000	-207,800,000
Research and development expenses	458,700,000	406,000,000	497,200,000
Income taxes	42,200,000	112,300,000	16,300,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	386,799	363,034	378,388

Board of Directors

Members of Management Board		
Christopher Begley	Chairman of Board of Directors	
Arthur Higgins	Member of Board of Directors	
Betsy Bernard	Member of Board of Directors	
Louis Shapiro	Member of Board of Directors	
Maria Hilado	Member of Board of Directors	
Michael Farrell	Member of Board of Directors	
Michael Michelson	Member of Board of Directors	
Robert Hagemann	Member of Board of Directors	
Sreelakshmi Kolli	Member of Board of Directors	
Syed Jafry	Member of Board of Directors	
Ivan Tornos	Chairman of Managing Board	
Angela Main	Member of Executive Committee	
David J. Kunz	Member of Executive Committee	
Kenneth R. Tripp	Member of Executive Committee	
Keri P. Mattox	Member of Executive Committee	
Lori Winkler	Member of Executive Committee	
Rachel H. Ellingson	Member of Executive Committee	
Sang Yi	Member of Executive Committee	
Suketu Upadhyay	Member of Executive Committee	
Wilfred van Zuilen	Member of Executive Committee	
Zeeshan Tariq	Member of Executive Committee	